Growth Metrics

Cellectis (CLLS) Gains from Investment Securities (2018 - 2025)

Cellectis (CLLS) posted Gains from Investment Securities of -$3.3 million for Q2 2025, down 455.77% on a QoQ basis from $927000.0 in Q1 2025.

Cellectis (CLLS) has 6 years of Gains from Investment Securities data on file, last reported at -$3.3 million in Q2 2025.

  • In Q2 2025, Gains from Investment Securities changed N/A year-over-year to -$3.3 million; the TTM figure through Jun 2025 stood at -$2.4 million (changed N/A YoY), while the FY2025 annual figure was -$1000.0, up 95.24% from the prior year.
  • Gains from Investment Securities eased to -$3.3 million in Q2 2025, from $927000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $927000.0 in Q1 2025 and bottomed at -$3.3 million in Q2 2025.
  • A 4-year average of -$503000.0 and a median of -$39000.0 in 2021 frame the typical range for Gains from Investment Securities.
  • The widest YoY moves for Gains from Investment Securities: up 58.06% in 2021, down 55.91% in 2021.
  • Year by year, Gains from Investment Securities stood at -$39000.0 in 2021, then sank by 2853.85% to -$1.2 million in 2022, then surged by 87.07% to -$149000.0 in 2023, then tumbled by 2113.42% to -$3.3 million in 2025.
  • The last three Gains from Investment Securities figures came in at -$3.3 million (Q2 2025), $927000.0 (Q1 2025), and -$149000.0 (Q2 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn
7 Evaxion A 64.16 Bn 64.14 Bn -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn
10 Cellectis 20.83 Bn 20.62 Bn -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2025 -3.30 Mn
Jun 30, 2025 -3.30 Mn
Mar 31, 2025 927,000.00
Mar 31, 2025 927,000.00
Jun 30, 2023 -149,000.00
Jun 30, 2023 -149,000.00
Mar 31, 2023 149,000.00
Mar 31, 2023 149,000.00
Dec 31, 2022 -1.15 Mn
Dec 31, 2022 -1.15 Mn
Jun 30, 2021 -39,000.00
Jun 30, 2021 -39,000.00
Mar 31, 2021 41,000.00
Mar 31, 2021 41,000.00
Dec 31, 2020 -58,000.00
Dec 31, 2020 -58,000.00
Sep 30, 2020 -20,000.00
Sep 30, 2020 -20,000.00
Jun 30, 2020 -93,000.00
Jun 30, 2020 -93,000.00
Mar 31, 2020 93,000.00
Mar 31, 2020 93,000.00
Dec 31, 2018 -438,000.00
Dec 31, 2018 -438,000.00